67 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
data on short term and chronic use of Proglycem in children with congenital hyperinsulinism, or CHI, and in adults with insulinoma. Insulinoma patients … symptom of PWS – hyperphagia – a chronic feeling of insatiable hunger. Other central effects of DCCR may improve various behavioral abnormalities
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
the capsule and IV formulations have been withdrawn from the U.S. market for reasons other than safety. There is extensive data on short term and chronic … the potential to address the hallmark symptom of PWS – hyperphagia – a chronic feeling of insatiable hunger. Other central effects of DCCR may improve various
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, food pre-occupation, extreme
8-K
EX-99.1
txuxv uq0
8 Aug 23
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:25pm
8-K
EX-99.1
0zquuzw7hltbtw51
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
2m1pvy cjjc0
9 May 23
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
8eb7l1d opsbj
3 May 23
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
5:26pm
8-K
EX-99.1
xqkxj143zvlqhwrpvqs
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
t4n9shx6l 7gb
9 Nov 22
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.1
rit1qrq4fx9t65emn119
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
8-K
EX-99.1
oo453uwjx zqyl
10 Aug 22
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
t9tnua dejn547s09
20 Jul 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:01am
8-K
EX-99.1
zxjj08mz
10 May 22
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:01pm
8-K
EX-99.1
84jqwqf tiygrxbgwm
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
vug2w
30 Mar 22
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
g71f ss9lfp
28 Mar 22
Soleno Therapeutics Announces Proposed Underwritten Public Offering
4:59pm
424B5
nfb0koxa32
28 Mar 22
Prospectus supplement for primary offering
4:53pm